The global ebstein’s anomaly market is expected to garner a market value of USD 13.90 Billion in 2023 and is expected to accumulate a market value of USD 30 Billion by registering a CAGR of 8% in the forecast period 2023-2033. The growth of Epstein’s anomaly market can be attributed to the increasing prevalence of people suffering from heart-related diseases. The market for Epstein's anomaly registered a CAGR of 4.5% in the historical period 2018 to 2022
The number of babies suffering from Epstein’s anomaly is increasing substantially. The unavailability of correct treatment and research for finding out suitable treatment and manufacturing medications is contributing to the growth of the market. Moreover, manufacturers of medications are investing in research and medication to treat the ailment at an early stage.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 13.90 Billion |
| Anticipated Forecast Value (2033) | USD 30 Billion |
| Projected Growth Rate (2023 to '2033) | 8% CAGR |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
According to market research and competitive intelligence provider Future Market Insights, the market for Ebstein’s anomaly reflected a value of 8% during the historical period, 2017 to 2022.
According to Cleveland Clinic, one in 200,000 babies is born with Epstein’s anomaly. With the world population increasing rapidly, the number of babies suffering from the ailment is expected to grow. Moreover, technological advancements and extensive research to manufacture medication for Epstein’s anomaly are expected to positively influence the demand for the market.
Thus, the market for Ebstein’s anomaly is expected to register a CAGR of 4.5% in the forecast period 2023 to 2033.
Genetic disorders and exposure to medications propelling cases of Epstein's anomaly market
Ebstein's anomaly is a rare congenital disease that occurs due to improper development of the tricuspid valve in the first eight weeks of fetal growth. This disorder occurs when the tricuspid valve that divides the two chambers of the right side of the heart does not form correctly.
Ebstein's anomaly may be due to many factors, including genetics and the environment. Children born in a family with a history of heart defects may be more likely to have Ebstein's anomaly. The mother's exposure to certain medications, such as lithium, can lead to Ebstein's anomaly in the child.
An increasing number of congenital diseases contributing to Epstein's anomaly market
The global Ebstein’s Anomaly market is driven by the increasing number of congenital heart diseases and the growing population; growing market players have increased the scope of Ebstein’s Anomaly market. Technological advancements, owing to which new and advanced products are being launched in the market, are another factor propelling the growth of this market.
Manufacturers of medication for Epstein’s anomaly are undertaking extensive research to form and produce medicines to treat or reduce the pain caused by the ailment. The integration of technology and knowledge is creating lucrative opportunities for the production of medication to treat ebstein’s anomaly.
Stringent regulatory frameworks for approval of medication hindering the market growth
The varied stringency of regulatory procedures across the globe and the presence of complex regulatory procedures may hinder the growth of this market. Moreover, the unavailability of correct medication and cause for the ailment is derailing the progress of the market. Furthermore, the lack of reasoning to produce medication that offers accurate results to treat ebstein’s anomaly is creating obstacles to the progress of the market.
Availability of skilled professionals and advanced treatment boosting the market growth in North America
North America Ebstein’s Anomaly market is rapidly growing in the American region. On a regional basis, the Americas are segmented into North America and South America. North America is segmented into the USA and Canada. An increasing number of congenital disorders and a growing population have increased the scope of Ebstein’s Anomaly market in North America.
According to CDC (Centre for Disease Control), it was estimated that about 1 Billion USA children and about 1.4 Billion USA adults were living with CHDs. Additionally, CHDs affect nearly 1% of? or about 40,000?births per year in the United States. In addition, the skilled professionals and availability of advanced and accessible treatment facilities. Additionally, wide research and development activities for the treatment of rare diseases and increasing government funding boost market growth. Thus, North America is expected to possess a 40% market share for einstein’s anomaly market in 2023.
Increasing healthcare expenditure boosting the growth of Ebstein’s anomaly market in the Asia Pacific
Asia Pacific is expected to be the fastest-growing market. The increasing prevalence of chronic diseases such as diabetes is the major driver for market growth. India is the fastest growing region owing to the increasing population. Rising awareness about the health and availability of new treatment methods drive the market in this region. Rising healthcare expenditure and overall growth of the healthcare diagnostic and treatment industry also drive the market.
The presence and availability of specialty care centers in countries like China and Japan along with extensive research activities undertaken to treat the ailment are driving the growth of the overall einstein’s anomaly market in the Asia Pacific region. Thus, Asia Pacific is expected to possess a 35% market share for einstein’s anomaly market in 2023.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
Precise results and ease of performing tests make echocardiogram a popular test option
On the basis of diagnosis Ebstein’s Anomaly market is segmented into echocardiogram, electrocardiogram (ECG) chest x-ray, cardiac MRI, Holter monitor, pulse oximetry, exercise stress test, electrophysiology study, and cardiac catheterization.
Echocardiogram has gained immense popularity owing to the accurate results it offers. The test uses sound waves to produce detailed images of the heart. Thus, it is a safer option to determine the presence of einstein’s anomaly in children. Furthermore, doctors too have recommended and favored the use of einstein’s anomaly owing to the ease of performing the test and the precise results it offers.
Thus, an echocardiogram is expected to possess a 33% market share for einstein’s anomaly market in 2023.
Favorable reimbursement policies make hospitals a viable option for treatment
On the basis of end users, the market is segmented into hospitals & surgical centers, and specialty clinics.
The hospital segment is expected to hold the largest market share for einstein’s anomaly. This is owing to the availability of various treatments and diagnostics in hospitals. In addition, the presence of healthcare experts and cardiologists is playing a key role in the wide usage of hospitals for the treatment of einstein’s anomaly.
In addition, initiatives by government authorities to support the treatment of einstein anomaly, especially in hospitals are favoring the growth of the same. Moreover, reimbursement schemes and their benefits are making hospitals a go-to option for the treatment of einstein’s anomaly. Thus, hospitals are expected to hold a 50% market share for einstein’s anomaly market in 2023.
Some of the key players in Ebstein’s anomaly market are Abbott Vascular, Boston Scientific Corporation, Cordis Corporation, Edwards Lifesciences, Ge Healthcare, Gore Medical, Medtronic, Inc., and Numed, Inc among others.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 13.90 Billion |
| Market Value in 2033 | USD 30 Billion |
| Growth Rate | CAGR of 8% from 2023 to 2033 |
| Base Year for Estimation | 2021 |
| Historical Data | 2017 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Treatment, Diagnosis, End User, Region |
| Regions Covered | North America; Latin America; Western Europe; Eastern Europe; Asia Pacific Excluding Japan; Japan; Middle East and Africa (MEA) |
| Key Countries Profiled | The USA, Canada, Brazil, Argentina, Germany, The UK, France, Spain, Italy, Nordics, BENELUX, Australia & New Zealand, China, India, Association of Southeast Asian Nations, GCC, South Africa |
| Key Companies Profiled | Abbott Vascular; Boston Scientific Corporation; Cordis Corporation; Edwards Lifesciences; Ge Healthcare; Gore Medical; Medtronic, Inc.,; Numed, Inc. |
| Customization | Available Upon Request |
From 2017 to 2022, the Ebstein’s anomaly market grew at a CAGR of 4.5%
The global Ebstein’s anomaly market is expected to grow with an 8% CAGR during 2023 to 2033.
As of 2033, the Ebstein’s anomaly market is expected to reach USD 30 Billion
The hospital’s segment is expected to hold 50% of the market share in 2023 for Ebstein’s anomaly market.
Echocardiogram is expected to possess 33% market share for eibstien’s anomaly market in 2023.
North America is expected to possess 40% market share for Ebstein’s anomaly market in 2023.
Asia Pacific Ebstein’s anomaly market size is expected to possess 35% market share in 2023.
| Market Size (2023) | USD 13.4 Million |
|---|---|
| Market Value (2033) | USD 20.7 Million |
| Value CAGR (2023 to 2033) | 4.5% |
| Market Value (2023) | USD 2.71 Billion |
|---|---|
| Market Projected Value (2033) | USD 10.88 Billion |
| Market CAGR (2023 to 2033) | 14.9% |
Explore Therapy Area Insights
View Reports
Ebstein’s Anomaly Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
